Home/Filings/4/0001689375-24-000068
4//SEC Filing

WENTWORTH KORY JAMES 4

Accession 0001689375-24-000068

CIK 0001689375other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 5:26 PM ET

Size

14.3 KB

Accession

0001689375-24-000068

Insider Transaction Report

Form 4
Period: 2024-11-29
WENTWORTH KORY JAMES
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-11-29$2.10/sh+1,000$2,10074,849 total
  • Sale

    Common Stock

    2024-11-29$19.97/sh1,000$19,97073,849 total
  • Sale

    Common Stock

    2024-12-02$20.00/sh5,000$99,97873,849 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-12-025,00031,157 total
    Exercise: $2.10Exp: 2030-11-10Common Stock (5,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-11-291,00036,157 total
    Exercise: $2.10Exp: 2030-11-10Common Stock (1,000 underlying)
  • Exercise/Conversion

    Common Stock

    2024-12-02$2.10/sh+5,000$10,50078,849 total
Footnotes (4)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The shares subject to this option fully vested on November 16, 2024.

Issuer

Entrada Therapeutics, Inc.

CIK 0001689375

Entity typeother

Related Parties

1
  • filerCIK 0001725663

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 5:26 PM ET
Size
14.3 KB